COMMUNIQUÉS West-GlobeNewswire

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
14/03/2024
Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) Accelerated approval was based on Phase 3 data demonstrating that Rezdiffra improved liver fibrosis [...]
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
14/03/2024
Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (AI)-powered medical technology [...]
Un premier extrait de cannabis médical approuvé au Portugal pour Tilray Medical
14/03/2024
CANTANHEDE, Portugal, 14 mars 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., ci-après « Tilray » ou la « Société » (Nasdaq : TLRY ; TSX : TLRY), un producteur mondial de premier ordre spécialisé dans le cannabis et les [...]
TerrAscend Reports Fourth Quarter and Full Year 2023 Financial Results
14/03/2024
Full year 2023 record Net Revenue of $317.3 million, an increase of 28.0% year-over-year Full year 2023 Gross Profit margin of 50.3%, a 930 basis-point improvement year-over-year Full year 2023 Adjusted EBITDA from [...]
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
14/03/2024
Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Evoke [...]
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
14/03/2024
PURCHASE, N.Y., March 14, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat [...]
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
14/03/2024
Interim data from initial dose escalation cohorts from Phase 1 trial of TERN-701 (allosteric BCR-ABL) for treatment of CML expected in second half of 2024 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for [...]
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
14/03/2024
Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024 IND application to evaluate ELVN-002 in combination with [...]
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
14/03/2024
Positive top-line data from Phase 2 dose exploration study of nomlabofusp, which was generally well-tolerated, with dose-dependent increases in tissue frataxin levels observed Initiated discussions with the Food and [...]
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
14/03/2024
Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL) : Start-Up Activities Underway; Enrollment to Begin Mid-2024 Cema-cel Phase 1 ALPHA2 Trial in Relapsed/Refractory Chronic [...]
Sensus Healthcare to Participate in the 36th Annual Roth Conference
14/03/2024
Management will discuss its new “Fair Deal Agreement” for its SRT-100 Vision ™ IG-SRT in one-on-one meetings in Dana Point, California on March 18 th and 19 th BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Sensus [...]
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14/03/2024
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, [...]
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
14/03/2024
Significant progress made in preparing for a Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator Topline data from Phase 1 norovirus study in lactating mothers [...]
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
14/03/2024
Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growth Full year 2023 revenues reached $31.6 million with product sales and [...]
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
14/03/2024
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to [...]
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
14/03/2024
Reported the First-Ever Durable Persistence of an Allogeneic Cellular Therapy from a Phase 1 Study of INB-100 in Leukemia where 100% of Evaluable Patients (n=10) Treated Remained in Remission, including six Patients [...]
Revolutionary Study at Ibogaine By David Dardashti Sheds Light on How Zodiac Signs Impact Treatment
14/03/2024
Quantum Physics and Astrology MIAMI, March 14, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti is proud to release the results of its lead researcher, Gavriel Dardashti's study analyzing the effects of astrological [...]
Full-year 2024 guidance suspended due to the temporary pause of API production at the Brindisi site in Italy
14/03/2024
Press Release Paris – March 14 th , 2024 – EUROAPI today announces that its Italian subsidiary, EUROAPI Italy S.R.L., is suspending the production of all APIs 1 in Brindisi. Following an internal audit, quality control [...]
Perspectives 2024 suspendues à la suite de l’arrêt temporaire de production d’API sur le site de Brindisi en Italie
14/03/2024
Communiqué de presse Paris – Le 14 mars 2024 – EUROAPI annonce aujourd’hui que sa filiale italienne EUROAPI Italy S.R.L. suspend la production de tous les APIs 1 sur son site de Brindisi. A la suite d’un audit interne, [...]

Pages